Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Chief Financial Officer Michael Ladurner to leave Intrum

Intrum AB (publ) has come to an agreement with Michael Ladurner, Chief Financial Officer (CFO), regarding his departure from the company.Anders Blomqvist has been appointed interim CFO with immediate effect, and Michael Ladurner will support the organisation to ensure a smooth CFO handover through the first quarter of 2024.“Michael has played an important role for Intrum during the last seven years. Joining as an investment professional, Michael was internally recruited to the CFO position 2021, with the mission to establish a solid financial structure and governance processes. Given the

Navamedic and Orion Corporation sign non-binding term sheet for Flexilev® in Europe

Oslo, 13. December 2023 - Navamedic ASA and Orion Corporation (“Orion”) have today signed a non-binding term sheet for a licensing- and supply agreement for Flexilev®, including the Orafid dispenser, across Europe, not including Sweden, Norway, Denmark, and Iceland, where Navamedic will market and sell the product. Flexilev® is a novel prescription treatment for Parkinson’s disease and was added to Navamedic’s product portfolio following the acquisition of Sensidose AB in May 2023.Orion and Navamedic have agreed to enter into a final agreement by the end of the first quarter of 2024. “

Saudi Electricity Company Accelerates its Sustainability Journey in the Kingdom using Digital & AI

Riyadh; Dec 2023: Saudi Electricity Company (SEC) has taken a significant step in its sustainability journey by signing a Memorandum of Understanding (MoU) with Net-Zero Technology Center (NZTC) and Accenture. The agreement aims to leverage digital and AI technologies to promote low-carbon solutions in the Kingdom and beyond.Together they will develop and launch a Sustainability Center of Excellence, to drive growth of low-carbon solutions and enable SEC’s Net-Zero targets by stimulating national innovation and entrepreneurship while upskilling the local workforce.  "Today marks a

Curasight A/S appoints CRO to run Phase 2 study with uTRACE[®] in prostate cancer

· Phase 2 study is part of the collaboration between Curasight and Curium announced earlier this year · Appointment of clinical CRO marks further step in progress in development of uTRACE as a potential new diagnostic solution for prostate cancer Copenhagen, December 13, 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) today announced it has signed an agreement with ABX-CRO, an experienced international clinical research organization serving the pharmaceutical industry, to run the phase 2 study investigating uTRACE[®] in improving the diagnosis of prostate cancer.

STENOCARE: The deadline for trading TO1 Warrants is Dec 15

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S (Stenocare) is currently offering new shares at a discounted rate of DKK 2.11 for TO1 Warrant owners and, through the acquisition of Warrants, new investors. The deadline for trading TO1 Warrants is end of business day December 15Deadline for trading TO1 Warrants: The important deadline for trading is December 15 at 16:59 (CET). Warrant owners who are not planning to exercise their TO1 Warrants have the opportunity to sell the warrants before the deadline. Investors that are interested in subscribing

NPRO: Equity issue NOK 500 million as part of the financing of the Telegrafen acquisition

The general meeting of Norwegian Property ASA has today resolved to increase the company's equity with NOK 500 million. The new share capital is subscribed by the company's sole shareholder, Geveran Trading Co. Limited. The issue is part of the refinancing of the existing bonds to Telegrafen Holding AS which was acquired in November.   Minutes of the extraordinary general meeting and updated articles of association are attached.

#23-390 Delisting of Derivatives from NGM

Information about certain derivatives that will be delisted from NGM.For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for

Quickbit eu AB (publ) adopts dividend policy

On 22 May 2023, the Extraordinary General Meeting in Quickbit eu AB (publ) ("Quickbit") resolved to instruct the Board of Directors to adopt a dividend policy for Quickbit. The Board of Directors of Quickbit has today, 13 December 2023, resolved to adopt the following dividend policy.· The board of directors' top priority is to ensure that Quickbit has a financial position strong enough to support both organic growth and selective acquisitions. In addition, Quickbit wants to maintain a strong balance sheet. The payment of capital to the shareholders must be adapted to profit development and

#23-389 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies

OncoZenge Announces Advisory Board with Dr Stephen Sonis and Dr Pooja Nandwani Patel

Stockholm, Sweden, December 13th 2023 – OncoZenge AB (publ) (Nasdaq First North Growth Market: ONCOZ), a leading biotechnology company developing BupiZenge™, an innovative therapy for treating oral pain, today announces the formation of an Advisory Board of renowned scientists and clinicians with expertise in oral medicine and cancer.The Advisory Board will provide strategic guidance and consultation to OncoZenge as it advances its research and development, with a focus on advancing BupiZenge™ through phase III studies and eventual market approval. The board's members bring a wealth of

Zwipe AS – preliminary results of the rights issue

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN ZWIPE AS. SEE ALSO THE SECTION "IMPORTANT INFORMATION" BELOW IN THIS DOCUMENT. OSLO, NORWAY – 13 DECEMBER 2023 – Reference is made to the stock exchange announcement published by Zwipe AS (the "Company") on 28 November 2023,

Director/PDMR Shareholding

12 December 2023 Redde Northgate plc (“Redde Northgate” or the “Company”) Director/PDMR Shareholding TRANSFER OF SHARES On 12 December 2023 Mark Butcher, a Non-Executive Director of the Company, transferred 5,400 ordinary shares in the Company between two share accounts in which he is the sole beneficial owner. No change to the number of shares beneficially held by the Director has occurred in connection with the transfer, and following the transfer the Director remains interested in 34,676 ordinary shares. The transfer was effected through the sale of 5,400 ordinary shares

Hamlet BioPharma Announces the Nomination of Elisabeth Parker to its Board of Directors

Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along with an extensive project and patent portfolio, is delighted to announce the nomination of Dr. Elisabeth Parker to its Board of Directors. Dr. Parker's nomination will bring business development, international pharmaceutical industry networks and leadership excellence to the company and strengthen the continued growth of Hamlet BioPharma. Dr. Elisabeth Parker is currently serving as a Senior Investment Advisor for Healthcare and Life Sciences

Teesside University secures funding for groundbreaking research in waste-to-energy

Two Teesside University academics have received funding for groundbreaking research investigating how to reduce the carbon footprint from waste-to-energy plants.Professor Dawid Hanak, in collaboration with Professor Kumar Patchigolla, has been granted funding from the UK Carbon Capture and Storage Research Community’s (UKCCSRC) Flexible Funding call to look at how carbon capture technology can be used alongside waste-to-energy (WtE) plants. [Professor Dawid Hanak] The research will address a critical need for the East Coast Cluster by assessing the techno-economic and carbon footprint

Smoltek Nanotech Holding AB (publ) resolves on the record date for allotment of warrants of series TO 8

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, BELARUS, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Smoltek Nanotech Holding AB (publ) ("Smoltek" or the "Company") announces that the record date for allotment of warrants of series TO 8 has been set to

Ovzon receives order of 135 MSEK from Swedish Space Corporation (SSC)

On November 21, Ovzon announced that the company was in ongoing negotiations with Swedish Space Corporation (SSC) regarding a large order. Today, Ovzon has received an order from SSC for Ovzon’s SATCOM-as-a-Service, including Ovzon mobile satellite terminals. The service will be delivered during large parts of 2024 with start in the first quarter, and the delivery of terminals will start immediately. The total order value amounts to 135 MSEK.Ovzon SATCOM-as-a-Service distinguishes itself in the market by its unique ability to support critical missions with assured connectivity that can

Veidekke: To continue district heating construction in Denmark

Veidekke's Danish subsidiary Hoffmann AS has signed a new agreement for the development and efficiency improvement of Gladsaxe Municipality’s district heating network. The contract with Gentofte/Gladsaxe Fjernvarme has a value of approx. DKK 300 million.The project in Gladsaxe, outside Copenhagen, will provide new groups of residents and businesses with a more reliable and energy-efficient district heating supply, which meets environmental requirements and reduces CO\2\ emissions. Work on the project will start in early 2024, with expected completion in 2027. The new agreement marks a

Tecnotree Oyj - Managers' Transactions

Tecnotree Corporation Stock Exchange Release 13 December 2023 at 17:00 EETPerson subject to the notification requirementName: Fitzroy Investments LimitedPosition: Closely associated person(X) Legal person  (1):Person Discharging Managerial Responsibilities In IssuerName: Neil MacleodPosition: Member of the BoardIssuer: Tecnotree OyjLEI: 743700MRPVYI7ASHCX38Notification type: INITIAL NOTIFICATIONReference number: 46024/4/4 ____________________________________________Transaction date: 2023-12-08Venue: OFF-EXCHANGE LIIKETOIMET (XOFF)Instrument type: DEBT INSTRUMENT

Stefan Axellie to leave role as CFO for Cell Impact AB

Stefan Axellie, CFO of Cell Impact since 2020, has decided to leave his role and Cell Impact by spring 2024.“I have spent four years with Cell Impact which have been both intensive and exiting, but I now feel that it is a good time for me to pursue other challenges,” explains Stefan Axellie. “Stefan has been a key member of Cell Impact’s executive management since 2020. He has strongly contributed to the company’s development and is an appreciated leader and colleague,” comments Pär Teike CEO, Cell Impact. The process of identifying a successor will start within short. Stefan Axellie

There are no items matching the current filter
There are no more items matching the current filter
Back to top